NCT01448200View on ClinicalTrials.gov

A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Hepatitis C, Chronic
Interventions
DRUG

PPI-668

capsules

DRUG

Placebo

capsules

Trial Locations (7)

Unknown

Investigational site, Costa Mesa

Investigational site, Sacramento

Investigational site, San Francisco

Investigational Site, San Antonio

Investigational site, Canberra

Investigational site, Auckland

Investigational site, Christchurch

Sponsors
All Listed Sponsors
lead

Presidio Pharmaceuticals, Inc.

INDUSTRY